Back to results
US 2019/0194331 A1Published application
Anti-vla1 (cd49a) antibody pharmaceutical compositions
AssigneeSantarus, Inc.
InventorsAdam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
Life of this patent
Estimating the term…
Abstract
Formulations of anti-VLA-1 antibodies are described.
Claims19
-20. (canceled)
A method of treating an inflammatory, immune, or autoimmune disorder in a patient comprising administering to the patient an effective amount of an aqueous antibody pharmaceutical composition comprising:
- (a) about 150 to about 210 mg/mL of an anti-VLA-1 (anti-Very Late Antigen-1) antibody, said antibody having one or both of:
- a light chain variable region having the amino acid sequence of SEQ ID NO:4 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:5;
- (b) 25 to 35 mM histidine;
- (c) 170 to 288 mM sorbitol;
- and
- (d) 0.008 to 0.012% polysorbate;
- and
- wherein the aqueous pharmaceutical composition has a pH of 5 to 7.
5 more elements
A method of treating an inflammatory disorder in a patient, said method comprising administering to said patient an effective amount of the aqueous pharmaceutical composition comprising:
- (a) about 150 to about 210 mg/mL of an anti-VLA-1 (anti-Very Late Antigen-1) antibody, said antibody having one or both of:
- a light chain variable region having the amino acid sequence of SEQ ID NO:4 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:5;
- (b) 25 to 35 mM histidine;
- (c) 170 to 288 mM sorbitol;
- and
- (d) 0.008 to 0.012% polysorbate;
- and
- wherein the aqueous pharmaceutical composition has a pH of 5 to 7.
5 more elements
Dependencies are inferred from the claim text.